Nosaki, Kaname

Publications

Sort by

Co-Author Network

selected publications

Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma. Cancer science. 2023 Academic Article GET IT
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid). Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Editorial Article GET IT
Times cited: 3
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma. Cancer immunology, immunotherapy : CII. 2023 Review GET IT
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands). 2023 Academic Article GET IT
Times cited: 1
Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Times cited: 2
The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Times cited: 1
Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study. The oncologist. 2022 Academic Article GET IT
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 13
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature. 2021 Academic Article GET IT
Times cited: 24
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science. 2021 Academic Article GET IT
Times cited: 3
Comparison of the efficiency of endobronchial ultrasound-guided transbronchial needle aspiration using a 22G needle versus 25G needle for the diagnosis of lymph node metastasis in patients with lung cancer: a prospective randomized, crossover study. Translational lung cancer research. 2021 Academic Article GET IT
Times cited: 49
High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 2
Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study. Thoracic cancer. 2021 Academic Article GET IT
Times cited: 19
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer medicine. 2021 Academic Article GET IT
Times cited: 4
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 12
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical lung cancer. 2021 Academic Article GET IT
Times cited: 3
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science. 2020 Academic Article GET IT
Times cited: 16
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO clinical and research reports. 2020 Review GET IT
Times cited: 13
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer. Journal of cancer research and clinical oncology. 2020 Academic Article GET IT
Times cited: 2
Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). The oncologist. 2020 Academic Article GET IT
Times cited: 11
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. Trials. 2020 Academic Article GET IT
Times cited: 4
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands). 2019 Academic Article GET IT
Times cited: 8
Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. Journal of thoracic disease. 2019 Academic Article GET IT
Times cited: 335
[Ⅱ.Management of Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors]. Gan to kagaku ryoho. Cancer & chemotherapy. 2019 Academic Article GET IT
Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. Thoracic cancer. 2019 Academic Article GET IT
Times cited: 5
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer (Amsterdam, Netherlands). 2019 Review GET IT
Times cited: 143
The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer. The Annals of thoracic surgery. 2019 Academic Article GET IT
Times cited: 6
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. 2019 GET IT
Times cited: 82
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. The oncologist. 2019 Academic Article GET IT
Times cited: 14
Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. Anticancer research. 2019 Academic Article GET IT
Times cited: 1
Pneumonectomy after induction chemoradiotherapy for locally advanced non-small cell lung cancer: should curative intent pulmonary resection be avoided?. Surgery today. 2019 Academic Article GET IT
Times cited: 5
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer science. 2018 Academic Article GET IT
Times cited: 21
Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018 Review GET IT
Times cited: 9
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018 Academic Article GET IT
Times cited: 34
A case of different EGFR mutations in surgically resected synchronous triple lung cancer. 2018 GET IT
Times cited: 11
A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report. Surgical case reports. 2017 Academic Article GET IT
Times cited: 64
Surgical resection of a well-differentiated inflammatory liposarcoma of the middle mediastinum: a case report. 2017 GET IT
Times cited: 31
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Cancer science. 2017 Academic Article GET IT
Times cited: 32
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget. 2017 Academic Article GET IT
Times cited: 59
Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. Oncology letters. 2017 Academic Article GET IT
Times cited: 554
Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report. Surgical case reports. 2017 Academic Article GET IT
Times cited: 615
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma. Clinical lung cancer. 2017 Academic Article GET IT
Times cited: 26
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 68
Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients. The Annals of thoracic surgery. 2016 Academic Article GET IT
Times cited: 13
A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. Molecular therapy oncolytics. 2016 Academic Article GET IT
Times cited: 27
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma. Anticancer research. 2016 Academic Article GET IT
Times cited: 8
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 115
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Investigational new drugs. 2016 Academic Article GET IT
Times cited: 52
c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report. Molecular and clinical oncology. 2016 Academic Article GET IT
Times cited: 8
Are Anthracycline-Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 9
The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer. Current treatment options in oncology. 2015 Academic Article GET IT
Times cited: 30
How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experience. Surgical oncology. 2015 Academic Article GET IT
Times cited: 18
Influence of the distance between home and the hospital on patients with surgically resected non-small-cell lung cancer. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2015 Academic Article GET IT
Times cited: 5
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. 2015 GET IT
Times cited: 50
Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer. Surgery today. 2015 Academic Article GET IT
Times cited: 5
Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncology letters. 2015 Academic Article GET IT
Times cited: 222
Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusion and/or pleural nodules: Ten-year results of a prematurely terminated single institute phase II trial. Surgical oncology. 2015 Academic Article GET IT
Times cited: 10
Role of surgical resection for patients with limited disease-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2015 Academic Article GET IT
Times cited: 59
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. 2014 GET IT
Times cited: 60
Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. Anticancer research. 2014 Academic Article GET IT
Times cited: 8
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 78
Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surgery today. 2013 Academic Article GET IT
Times cited: 28
LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma. Japanese journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 14
Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report. 2011 GET IT
Times cited: 4
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors. Archives of drug information. 2011 Academic Article GET IT
Times cited: 16
Incidentally proven pulmonary "ALKoma". 2010 GET IT
Times cited: 5

more ...

less ...

Background

education and training

Ph.D., Kyushu University (Japan) 2017
M.D., Kyushu University Faculty of Medicine (Japan) 2005

Contact

full name

Kaname Nosaki

primary email

kan4007@med.cornell.edu

VIVO Weill Cornell Medical College

Kaname Nosaki Postdoctoral Associate in Cardiothoracic Surgery

Publications

selected publications

Background

education and training

Contact

full name

primary email